Gastroenterology and General Medical Trials
Gastroenterology and General Medical Trials
We have particular specialisation in gastroenterology clinical trials which include rare conditions that would be difficult and very time-intensive to capture through the usual university or public health system processes. Carrying out such trials can be extremely resource intensive and Sydney Clinical Trials has been established to provide access to clinical trials for this group. This is very helpful for both our sponsors and for our participants who are seeking to access clinical trials as an integral part of clinical service provision for improved patient outcomes.
No trials available
Forte Bioscience Clinical Study
Have you been diagnosed with coeliac disease and still have symptoms despite following a gluten-free diet? You might be eligible to join a clinical trial.
This study is testing a new treatment for Coeliac disease, an autoimmune disorder that affects people who have a genetic tendency to react to food that contains gluten. Coeliac disease develops when the body’s immune cells react to gluten, a protein found in wheat, barley and rye. When the immune cells detect this protein, they trigger more of the immune system which leads to inflammation and tissue damage in the small intestine.
Physical Condition
Male and female patients aged 18 to 70 years who have a biopsy- and blood test-confirmed diagnosis of Coeliac disease and a body mass index (BMI) between 16.0 and 40.0 kg/m².
Requirements
There is no cost to participate.
This clinical trial is being run at Sydney Clinical Trials.
Eupraxia Pharmaceuticals Clinical Study
Do you have pain and difficulty with swallowing? You might be eligible to participate in a clinical trial.
Eosinophilic Esophagitis (EoE) is a condition of the oesophagus (tube from your mouth to stomach) that can lead to difficulty swallowing and causing food to get stuck in your throat while swallowing. A type of white blood cell, called an eosinophil, builds up in the lining of your oesophagus and causes inflammation. Eupraxia Pharmaceuticals is conducting a clinical study to test a new treatment called EP-104IAR which has been formulated as an injection into the oesophagus aimed to help those experiencing these symptoms of EoE.
Physical Condition
Male and female patients of age 18 years to 75 years old who have been diagnosed with Eosinophilic Esophagitis and have active symptoms of Eosinophilic Esophagitis.
Requirements
There is no cost to participate.
This clinical trial is being run at Sydney Clinical Trials.